Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-O: Durvalumab + Chemotherapy + Bevacizumab Followed by Maintenance in Advanced Ovarian Cancer
NCT03737643Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 20
01
Overview
A Phase 3 trial of durvalumab, olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Jan 2019; status: active, not recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03737643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03737643.